Publisher
Springer International Publishing
Reference43 articles.
1. Ali TB, Schieret TR, Reillu BM, Chen WY, Abagyan R. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United States and Canada. PLoS One. 2015:e0144337. https://doi.org/10.1371/journal.pone.0144337.
2. Berk C, Sabbagh M. Broader considerations of higher doses of donepezil in the treatment of mild, moderate and severe Alzheimer’s disease. Int J Alzheimer’s disease. 2012;2012:707468. https://doi.org/10.1155/2012/707468.
3. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2019;6:CD001190.
4. Birks JS, Chong LY, Evans JG, Cochrane Dementia and Cognitive Improvement Group. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;9:CD001191. https://doi.org/10.1002/14651858.CD001191.pub4.
5. Carney G, Bassett K, Wright JM, Maclure M, McGuire N, Dormuth CR. Comparison of cholinesterase inhibitor safety in real-world practice. Alzheimer’s Dement Trans Res Clin Interv. 2019;5:732–9.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献